No Result
View All Result
Success American Investors
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Success American Investors
No Result
View All Result
Home Investing

Dame Kate Bingham Celebrates ‘Astonishing’ $3bn Deal for EyeBio

by
May 30, 2024
in Investing
0
Dame Kate Bingham Celebrates ‘Astonishing’ $3bn Deal for EyeBio
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

In a landmark deal for the biotech industry, EyeBio, a London-based startup co-founded by Dame Kate Bingham, has been acquired by US pharmaceutical giant Merck, known as MSD in the UK, for up to $3bn (£2.36bn).

This acquisition is poised to revolutionise treatments for blindness.

Merck has committed to an initial payment of $1.3bn (£1bn) for EyeBio, with an additional $1.7bn contingent on achieving certain milestones. The rapid success of EyeBio, which raised just $130m since its founding in August 2021, has been described as “astonishing” by Dame Kate Bingham.

Bingham’s venture capital firm, SV Health Investors, established EyeBio in collaboration with scientists David Guyer and Tony Adamis. Since its inception, Dame Kate has served as the company’s chairman, leveraging her prominent profile as one of the key figures behind the UK’s successful Covid-19 vaccine rollout.

Dame Bingham was instrumental in leading the UK’s Vaccine Taskforce in early 2020, earning a damehood for her efforts in securing Covid-19 vaccines, which enabled the UK to become the first Western country to begin vaccinating its population in late 2020. She stepped down from this role at the end of 2020 and returned to her position at SV Health Investors as a managing partner.

The acquisition by Merck is expected to accelerate the development of EyeBio’s innovative treatments for eye diseases. EyeBio’s primary focus has been on diabetic macular oedema and age-related macular disease, two of the most prevalent causes of blindness in the Western world. Dame Kate told the Financial Times that the company’s drugs have the potential to “revolutionise the treatment” of these conditions.

David Guyer, EyeBio’s Chief Executive and President, highlighted the benefits of the acquisition: “As a subsidiary of Merck, EyeBio will be positioned to tap into the resources and infrastructure needed to support the clinical, regulatory, and commercial development of these candidates and help bring them to patients worldwide.”

Merck’s acquisition of EyeBio aligns with its strategy to enhance its drug pipeline, particularly as its blockbuster cancer drug nears the end of its patent. This deal not only signifies a major advancement for EyeBio but also underscores the critical role of innovative biotech companies in transforming healthcare outcomes.

Read more:
Dame Kate Bingham Celebrates ‘Astonishing’ $3bn Deal for EyeBio

Previous Post

UK Households with No Work Reach 12-Year High Amid Labour Crisis

Next Post

Millennial Homeownership Reaches 12-Year High Amid Rising Wages

Next Post
Millennial Homeownership Reaches 12-Year High Amid Rising Wages

Millennial Homeownership Reaches 12-Year High Amid Rising Wages

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest
Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

February 14, 2024
Idaho Bucks Managed Care Trend

Idaho Bucks Managed Care Trend

December 5, 2023

The Producer Price Index

September 9, 2023

CMKE Introduces PPM Subscription Model to Drive Cost Savings for Scottish Businesses

November 9, 2023
Friday Feature: MCP Academy

Friday Feature: MCP Academy

0

0

0

0
Friday Feature: MCP Academy

Friday Feature: MCP Academy

May 9, 2025

P.T. Bauer’s Reminders on Foreign Aid

May 9, 2025
Luna Introduces PATRIOT Act Repeal Bill

Luna Introduces PATRIOT Act Repeal Bill

May 9, 2025
In Congress, a Move To Strip Courts of Contempt Powers

In Congress, a Move To Strip Courts of Contempt Powers

May 9, 2025

Recent News

Friday Feature: MCP Academy

Friday Feature: MCP Academy

May 9, 2025

P.T. Bauer’s Reminders on Foreign Aid

May 9, 2025
Luna Introduces PATRIOT Act Repeal Bill

Luna Introduces PATRIOT Act Repeal Bill

May 9, 2025
In Congress, a Move To Strip Courts of Contempt Powers

In Congress, a Move To Strip Courts of Contempt Powers

May 9, 2025

Disclaimer: SuccessAmericanInvestors.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 SuccessAmericanInvestors. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 SuccessAmericanInvestors. All Rights Reserved.